Robert Forgey, MBA
Chief Operating Officer
Mr. Forgey graduated Beta Gamma Sigma from Olin School of Business, Washington University in 2001. He holds both a Bachelor's and a Master's degree in Biology from the University of North Dakota. He has 15 years pharmaceutical industry experience in research and development with G.D. Searle, Pharmacia and Pfizer development. His responsibilities have been in molecular biology methods development, project support, business management and financial control of discovery research organizations. Mr. Forgey most recently served as Manager, Discovery Financial Business Administration/Senior Financial Analyst with Pfizer-Pharmacia. Prior to this he served as Leader, Oncology Operations in Pharmacia Discovery.

Donald C. Anderson, MD
Chief Medical Officer
Dr. Anderson has over 32 years of prestigious and award-winning service in life sciences industrial and academic environments, most recently serving as VP Discovery Research at Advancis Pharmaceutical Corporation, following a term as Global Head of Pharmacogenomics at Aventis Pharmaceuticals. Dr. Anderson has also served in executive capacities at Pharmacia & Upjohn, as well as held a 20-year professorship at the Baylor College of Medicine.

J. Patrick McGovren, PhD
VP, Preclinical Development
Dr. McGovren is a longtime and well-known cancer research specialist, holding senior positions in big pharma oncology departments, as well as extensive consulting experience. Prior to joining ProNAi, Dr. McGovren was most recently Research Director, Clinical Pharmacology, Medical Development at Pfizer, following a term as Clinical Research Manager, Oncology Medical Affairs at Pharmacia. Between 1976 and 2000, Dr. McGovren held numerous senior research and management posts at Pharmacia & Upjohn.

Wendi V. Rodrigueza, PhD
VP, Product Development
Dr. Rodrigueza, whose therapeutic research expertise includes cardiovascular disease, oncology, diabetes and metabolic diseases, joins ProNAi after most recently serving at Novartis Institute of Biomedical Research, Inc. (NIBRI) as Director, Product Management, Cardiovascular Disease Area. Prior to NIBRI, Dr. Rodrigueza held numerous senior research positions at both CuraGen and Esperion Therapeutics (now a division of Pfizer Global Research and Development).